We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Acute Lymphoblastic Leukemia Risk Linked to Genetically Mediated Increase in Lymphocytes

By LabMedica International staff writers
Posted on 15 Sep 2021
Print article
Image: Acute lymphoblastic leukemia: bone marrow aspirate smear reveals increased blasts which are small to medium in size with high nuclear-to-cytoplasmic ratios, round to irregular nuclei, smooth chromatin, and scant basophilic agranular cytoplasm. Some background maturing myeloid cells are also present in this case (Photo courtesy of Karen M. Chisholm, MD, PhD)
Image: Acute lymphoblastic leukemia: bone marrow aspirate smear reveals increased blasts which are small to medium in size with high nuclear-to-cytoplasmic ratios, round to irregular nuclei, smooth chromatin, and scant basophilic agranular cytoplasm. Some background maturing myeloid cells are also present in this case (Photo courtesy of Karen M. Chisholm, MD, PhD)
Acute lymphoblastic leukemia (ALL) is a cancer of the lymphoid line of blood cells characterized by the development of large numbers of immature lymphocytes. As an acute leukemia, ALL progresses rapidly and is typically fatal within weeks or months if left untreated.

ALL is the most common cancer among children under 15 years old and is thought to develop under a two-hit model, under which a preleukemic clone develops in utero and a second somatic mutation then spurs the development of leukemia. While some genetic risk loci linked to ALL include variants in genes that have also been associated with hematopoiesis, lymphoid development, and blood-cell traits.

Genetic Epidemiologists at the University of Southern California (Los Angeles, CA, USA) and their colleagues investigated the etiological relevance of dysregulated blood-cell homeostasis in a genome-wide association study (GWAS) of childhood ALL (2,666 affected individuals, 60,272 control individuals) and a multi-trait GWAS of nine blood-cell indices in the UK Biobank. They examined blood cell traits such as lymphocyte, platelet, and neutrophil counts, as well as neutrophil-to-lymphocyte ratios and platelet-to-lymphocyte ratios.

The investigators reported that about 3,000 genetic variants were associated with one or more of these hematological traits and explained between 4% and nearly 24% of the variation in those traits. Additionally, 115 loci were linked to blood-cell ratios. They uncovered positive correlations between increased lymphocyte counts, lymphocyte-to-monocyte ratio, and neutrophil levels with ALL risk, and an inverse correlation between a higher platelet-to-lymphocyte ratio and ALL risk.

A clustering analysis identified two putative novel ALL risk variants from among those associated with blood cell traits, one on chromosome 2q22.1 and one within the FLT3 gene on 13q12.2. The scientists noted that variants within FLT3 have recently been linked to an increased risk of autoimmune thyroid disease and acute myeloid leukemia (AML). The allele linked to both ALL and AML risk lead to a truncated FLT3 protein, but an increase in FLT3 ligand levels. While this variant has a greater effect on the development of myeloid cells, they said it could also affect ALL risk through its activation of the RAS/MAPK pathway.

The authors concluded that their study showed that a genetically induced shift toward higher lymphocyte counts, overall and in relation to monocytes, neutrophils, and platelets, confers an increased susceptibility to childhood ALL. The study was published on August 31, 2021 in the American Journal of Human Genetics.

Related Links:
University of Southern California

Gold Member
Troponin T QC
Troponin T Quality Control
Verification Panels for Assay Development & QC
Seroconversion Panels
New
FOB+Transferrin+Calprotectin+Lactoferrin Test
CerTest FOB+Transferrin+Calprotectin+Lactoferrin Combo Test
New
Creatine Kinase-MB Assay
CK-MB Test

Print article

Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.